Araştırma Makalesi
BibTex RIS Kaynak Göster

Sarkoidozlu hastalarda plazma protaşikinin-1 (TAC1) düzeyleri

Yıl 2020, Cilt: 5 Sayı: 3, 76 - 81, 18.11.2020

Celalettin Korkmaz Turan Akdağ

https://doi.org/10.22391/fppc.779394

Öz

Giriş: Çok sayıda insanı etkileyebilen, sistemik granülomatöz bir akciğer hastalığı olan sarkoidozun etiyolojisi ve patogenezi hala tam olarak bilinmemektedir. Tanısı non-kazeöz granülomların gösterilmesi ve diğer granülomatöz hastalıkların dışlanmasıyla konulmaktadır. Bu nedenle tanı ve takipte kullanılabilecek hassas biyobelirteçlere ihtiyaç vardır. Bu çalışmanın amacı sarkoidozlu hastalarda plazma protaşikinin-1 düzeyinin tanı değerini araştırmaktır.

Yöntem: Göğüs hastalıkları kliniğince takipli 42 sarkoidozlu hasta ve 38 kişilik kontrol grubu çalışmaya dahil edildi. Tüm hastaların klinik, radyolojik ve laboratuvar verileri kaydedildi. Sarkoidoz hastalarında ve sağlıklı kontrol grubunda plazma protaşikinin-1 düzeyleri incelendi.

Bulgular: Sarkoidoz hastalarının ve kontrol grubunun plazma protaşikinin-1 düzeyleri sırasıyla 1124.25±1117.25 ng/L, 1319.37±1357.38 ng/L olarak bulundu. İstatistiksel olarak anlamlı olmamasına rağmen (p=0.338) sarkoidoz hastalarında protaşikinin-1 düzeyinde azalma saptandı. Ek olarak hastaların lenfosit düzeyleri de kontrol grubuna göre anlamlı olarak düşük bulundu (p=0.007). Diğer laboratuvar bulguları (lökosit, nötrofil, monosit, eozinofil sayısı, CD4 +, CD8 +, bronkoalveoler lavaj (BAL) CD4 +, BAL CD8 +, nötrofil / lenfosit oranı) ile de plazma protaşikinin-1 arasında istatistiksel olarak anlamlı korelasyon bulunmadı.

Sonuç: Literatür taramamıza göre çalışmamız sarkoidozlu hastalarda bir biomarker olarak plazma protaşikinin-1 düzeylerini araştıran ilk çalışmadır. Sarkoidozlu hastalarda plazma protaşikinin-1 düzeyi hafif azalsa da istatistiksel olarak anlamlı bulunmamış ve bir biomarker olarak kullanılabilmesi için yeterli veri sağlanamamıştır. Bu konuda daha fazla ve kapsamlı araştırmalara ihtiyaç vardır.

Anahtar Kelimeler

sarkoidoz akciğer hastalıkları granülom protaşikinin taşikininler bronkoalveoler lavaj

Kaynakça

  • 1. Jones N, Mochizuki M. Sarcoidosis: epidemiology and clinical features. Ocul Immunol Inflamm 2010;18(2):72-9. https://doi.org/10.3109/09273941003710598
  • 2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357(21): 2153-65. https://doi.org/10.1056/NEJMra071714
  • 3. Grunewald J, Grutters JC, Arkema E V, Saketkoo LA, Moller DR, Müller QJ. Sarcoidosis. Nat Rev Dis Primers 2019;5(1):45. https://doi.org/10.1038/s41572-019-0096-x
  • 4. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 2009;55(11):649-60. https://doi.org/10.1016/j.disamonth.2009.04.008
  • 5. Nazarullah A, Nilson R, Maselli DJ, Jagirdar J. Incidence and aetiologies of pulmonary granulomatous inflammation: a decade of experience. Respirology 2015;20(1):115-21. https://doi.org/10.1111/resp.12410
  • 6. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. Faseb J 1990;4(6):1606-15. https://pubmed.ncbi.nlm.nih.gov/1969374/
  • 7. Maggio JE. Tachykinins. Annu Rev Neurosci 1988;11:13-28. https://doi.org/10.1146/annurev.ne.11.030188.000305
  • 8. Dwivedi S, Purohit P, Misra R, Pareek P, Goel A, Khattri S, et al. Diseases and molecular diagnostics: a step closer to precision medicine. Indian J Clin Biochem 2017;32(4):374-98. https://doi.org/10.1007/s12291-017-0688-8
  • 9. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160(2):736-55. https://doi.org/10.1164/ajrccm.160.2.ats4-99
  • 10. Ahmadzai, H., Huang, S., Steinfort, C., Markos, J., Allen, R. K., Wakefield, D., et al., Sarcoidosis: a state of the art review from the Thoracic Society of Australia and New Zealand. Med J Aust 2018;208(11):499-504. https://doi.org/10.5694/mja17.00610
  • 11. Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018;9(11):227-40. https://doi.org/10.1177%2F2040622318790197
  • 12. Moller DR. Systemic sarcoidosis. Fishman’s pulmonary diseases and disorders. 1998:1125-42.
  • 13. Timmermans WM, Van Laar JA, Van Hagen PM, Van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunol 2016;5(12):e118. https://doi.org/10.1038/cti.2016.75
  • 14. Fischer A, Mc Gregor GP, Saria A, Philippin B, Kummer W. Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. J Clin Invest 1996;98(10):2284-91. https://doi.org/10.1172/JCI119039
  • 15. Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer, A. Tachykinins in the respiratory tract. Curr Drug Targets 2006;7(8):1005-10. https://doi.org/10.2174/138945006778019318
  • 16. Tillmaand EG, Anapindi KDB, De La Toba EA, Guo CJ, Krebs J, Lenhart AE, et al. Quantitative characterization of the neuropeptide level changes in dorsal horn and dorsal root ganglia regions of the murine ıtch models. J Proteome Res 2020;19(3):1248-57. https://doi.org/10.1021/acs.jproteome.9b00758
  • 17. Bleier B. Editorial: Blending medical and surgical therapies to optimize patient outcomes in chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy 2014;28(4):279-80. https://doi.org/10.2500%2Fajra.2014.28.4089

Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis

Yıl 2020, Cilt: 5 Sayı: 3, 76 - 81, 18.11.2020

Celalettin Korkmaz Turan Akdağ

https://doi.org/10.22391/fppc.779394

Öz

Introduction: The etiology and pathogenesis of sarcoidosis, a systemic granulomatous lung disease affecting many people, still remain unknown. Sarcoidosis is diagnosed by demonstrating non-caseous granulomas and ruling out granulomatous diseases. Therefore, sensitive biomarkers used in diagnosis and follow-up processes are needed. Our aim is to investigate diagnostic value of plasma protachykinin-1 (TAC1) levels in sarcoidosis patients.

Methods: Forty-two sarcoidosis patients followed-up by the department of chest diseases, and 38 controls were included into the study. Clinical, radiological and laboratory data of patients were recorded, and plasma TAC1 levels were analyzed in patients and healthy controls. 

Results: Plasma TAC1 levels of sarcoidosis patients and controls were found as 1124.25±1117.25 ng/L and 1319.37±1357.38 ng/L, respectively. Although not statistically significant (p=0.338), a decrease was found in TAC1 levels of sarcoidosis patients. Additionally, patients’ lymphocyte levels were also found significantly lower than controls (p=0.007). No statistically significant correlation was found between other laboratory findings, including leukocyte, neutrophil, monocyte, eosinophil count, cluster of differentiation 4 (CD4) CD4 +, CD8 +, bronchoalveolar lavage (BAL) CD4 +, BAL CD8 + and neutrophil/lymphocyte ratio (NLR), and plasma TAC1 levels.

Conclusions: To the best of our knowledge, our study is the first to investigate plasma TAC1 levels as a biomarker in sarcoidosis patients. Although plasma TAC1 levels were slightly decreased in sarcoidosis patients, the decrease was not statistically significant, and no adequate data were provided for the use of plasma TAC1 level as a biomarker. We consider more comprehensive research are needed to elucidate the entity.

Anahtar Kelimeler

sarcoidosis lung diseases granuloma protachykinin tachykinins bronchoalveolar lavage

Kaynakça

  • 1. Jones N, Mochizuki M. Sarcoidosis: epidemiology and clinical features. Ocul Immunol Inflamm 2010;18(2):72-9. https://doi.org/10.3109/09273941003710598
  • 2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357(21): 2153-65. https://doi.org/10.1056/NEJMra071714
  • 3. Grunewald J, Grutters JC, Arkema E V, Saketkoo LA, Moller DR, Müller QJ. Sarcoidosis. Nat Rev Dis Primers 2019;5(1):45. https://doi.org/10.1038/s41572-019-0096-x
  • 4. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 2009;55(11):649-60. https://doi.org/10.1016/j.disamonth.2009.04.008
  • 5. Nazarullah A, Nilson R, Maselli DJ, Jagirdar J. Incidence and aetiologies of pulmonary granulomatous inflammation: a decade of experience. Respirology 2015;20(1):115-21. https://doi.org/10.1111/resp.12410
  • 6. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. Faseb J 1990;4(6):1606-15. https://pubmed.ncbi.nlm.nih.gov/1969374/
  • 7. Maggio JE. Tachykinins. Annu Rev Neurosci 1988;11:13-28. https://doi.org/10.1146/annurev.ne.11.030188.000305
  • 8. Dwivedi S, Purohit P, Misra R, Pareek P, Goel A, Khattri S, et al. Diseases and molecular diagnostics: a step closer to precision medicine. Indian J Clin Biochem 2017;32(4):374-98. https://doi.org/10.1007/s12291-017-0688-8
  • 9. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160(2):736-55. https://doi.org/10.1164/ajrccm.160.2.ats4-99
  • 10. Ahmadzai, H., Huang, S., Steinfort, C., Markos, J., Allen, R. K., Wakefield, D., et al., Sarcoidosis: a state of the art review from the Thoracic Society of Australia and New Zealand. Med J Aust 2018;208(11):499-504. https://doi.org/10.5694/mja17.00610
  • 11. Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018;9(11):227-40. https://doi.org/10.1177%2F2040622318790197
  • 12. Moller DR. Systemic sarcoidosis. Fishman’s pulmonary diseases and disorders. 1998:1125-42.
  • 13. Timmermans WM, Van Laar JA, Van Hagen PM, Van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunol 2016;5(12):e118. https://doi.org/10.1038/cti.2016.75
  • 14. Fischer A, Mc Gregor GP, Saria A, Philippin B, Kummer W. Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. J Clin Invest 1996;98(10):2284-91. https://doi.org/10.1172/JCI119039
  • 15. Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer, A. Tachykinins in the respiratory tract. Curr Drug Targets 2006;7(8):1005-10. https://doi.org/10.2174/138945006778019318
  • 16. Tillmaand EG, Anapindi KDB, De La Toba EA, Guo CJ, Krebs J, Lenhart AE, et al. Quantitative characterization of the neuropeptide level changes in dorsal horn and dorsal root ganglia regions of the murine ıtch models. J Proteome Res 2020;19(3):1248-57. https://doi.org/10.1021/acs.jproteome.9b00758
  • 17. Bleier B. Editorial: Blending medical and surgical therapies to optimize patient outcomes in chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy 2014;28(4):279-80. https://doi.org/10.2500%2Fajra.2014.28.4089
Toplam 17 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Solunum Hastalıkları
Bölüm Araştırma Makalesi (Original Article)
Yazarlar

Celalettin Korkmaz 0000-0001-8602-0368

Turan Akdağ 0000-0003-3175-6751

Yayımlanma Tarihi 18 Kasım 2020
Gönderilme Tarihi 11 Ağustos 2020
Kabul Tarihi 15 Aralık 2020
Yayımlandığı Sayı Yıl 2020Cilt: 5 Sayı: 3

Kaynak Göster

APA Korkmaz, C., & Akdağ, T. (2020). Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis. Family Practice and Palliative Care, 5(3), 76-81. https://doi.org/10.22391/fppc.779394
AMA Korkmaz C, Akdağ T. Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis. Fam Pract Palliat Care. Aralık 2020;5(3):76-81. doi:10.22391/fppc.779394
Chicago Korkmaz, Celalettin, ve Turan Akdağ. “Plasma Levels of Protachykinin-1 (TAC1) in Patients With Sarcoidosis”. Family Practice and Palliative Care 5, sy. 3 (Aralık 2020): 76-81. https://doi.org/10.22391/fppc.779394.
EndNote Korkmaz C, Akdağ T (01 Aralık 2020) Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis. Family Practice and Palliative Care 5 3 76–81.
IEEE C. Korkmaz ve T. Akdağ, “Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis”, Fam Pract Palliat Care, c. 5, sy. 3, ss. 76–81, 2020, doi: 10.22391/fppc.779394.
ISNAD Korkmaz, Celalettin - Akdağ, Turan. “Plasma Levels of Protachykinin-1 (TAC1) in Patients With Sarcoidosis”. Family Practice and Palliative Care 5/3 (Aralık 2020), 76-81. https://doi.org/10.22391/fppc.779394.
JAMA Korkmaz C, Akdağ T. Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis. Fam Pract Palliat Care. 2020;5:76–81.
MLA Korkmaz, Celalettin ve Turan Akdağ. “Plasma Levels of Protachykinin-1 (TAC1) in Patients With Sarcoidosis”. Family Practice and Palliative Care, c. 5, sy. 3, 2020, ss. 76-81, doi:10.22391/fppc.779394.
Vancouver Korkmaz C, Akdağ T. Plasma levels of protachykinin-1 (TAC1) in patients with sarcoidosis. Fam Pract Palliat Care. 2020;5(3):76-81.

Family Practice and Palliative Care      ISSN 2458-8865       E-ISSN 2459-1505